D
Durect Corp.
Specialty pharmaceutical company developing innovative drugs for pain and chronic diseases, with late-stage development
About Durect Corp.
DURECT Corporation is a biopharmaceutical company focused on developing innovative therapies for acute organ injury and chronic liver diseases. The company leverages its epigenetic regulator program and proprietary drug delivery technologies to create novel treatments for diseases with limited current options. DURECT's pipeline includes DUR-928, the first endogenous epigenetic regulator clinically tested for treating acute organ injury and chronic liver diseases, and other investigational drugs like a non-opioid analgesic for post-surgical pain relief and a tamper-resistant ADHD medication. The company operates in the healthcare and pharmaceutical markets, primarily serving patients with unmet medical needs. DURECT generates revenue through the development and commercialization of its drug candidates, as well as through partnerships and licensing agreements.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1998
- Headquarters
- Cupertino, United States
- Listing
- IPO 2000
- Employees
- 73
- Open positions
- None listed
- Dealroom signal
- 62.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Apr 2001
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jul 2025 | $63M | — | Bausch Health Companies | ↗ |
| POST IPO EQUITYOther financing | Jul 2023 | $15M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $2M | 0% | −$19M | -911.1% |
| 2025 | $2M | 0% | −$19M | -911.1% |
| 2024 | $2M | -76.2% | −$19M | -911.1% |
| 2023 | $8.5M | -55.7% | −$35M | -406.2% |
| 2022 | $19M | +38% | −$33M | -170.8% |
| 2021 | $14M | -53.6% | −$34M | -244.1% |
| 2020 | $30M | — | −$12M | -40.2% |
Growth signals
Latest recorded traffic for Durect Corp. is 110 monthly website visits, down 92.7% over the last three months. Durect Corp.'s team declined 6.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- ZGZesiger Capital Group
Bain Capital
CHL Medical Partners
Series B and later1 investor entered at this stage
Oxford Finance
Other known investors1 additional known investor
Bausch Health Companies
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Durect Corp. on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Durect Corp.’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.